EAHP represents over 29,000 hospital pharmacists across 36 member countries. EAHP represents and develops the hospital pharmacy profession within Europe in order to ensure the continuous improvement of care and outcomes for patients in the hospital setting. This is achieved through science, research, education, practice, as well as sharing best-practice and responsibility with other healthcare professionals.
The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
The EAHP staff supports the Board in executing EAHP’s mission. The Staff assists in financial management, events organisations, policy activities and all EAHP projects. The EAHP staff works closely with EAHP’s members and ensures the effective communication all relevant stakeholders.
The first member countries were Belgium, Britain, Denmark, France, the Federal Republic of Germany and The Netherlands in 1972. EAHP has now 36 EAHP members and 2 Associate Members. EAHP is open to countries members of the Council of Europe and since 2022 to organisations representing the interests of hospital pharmacists from outside the Council of Europe (Associate Membership)
EAHP’s structure is also composed by different standing committes: EAHP Scientific Committee, EAHP Education Executive Committee and the EAHP CTF Steering Committee.
At EAHP, we are committed to transparency in our governance, ethical standards, and funding practices. This section provides open access to our foundational documents, including the EAHP Statutes, Code of Conduct, and Funding Sources. By sharing these resources, we aim to uphold accountability and foster trust with our members, partners, and the public.
Keep up with all EAHP’s events and webinars. Contact the team at info@eahp.eu should you have any questions about upcoming events or activities.
Here you can find all upcoming events organised by EAHP and by all its members and associate members. Do not hesitate to contact the events team at events@eahp.eu should you have any questions about the organisation of these events.
Hospital pharmacists conduct a critical role in the care of patients in hospitals. Learn more about what they do here and in all the pages under Hospital Pharmacy practice and Policy.
Self-Assessment
SILCC
Closed SIGs
EAHP brings together experts from many areas of hospital pharmacy practice providing and highlighting good local sustainable practices as that can be up-scaled and shared with other countries. The EAHP Working Group on Sustainability has the aim of reducing the environmental burden of the hospital pharmacy services.
The European Association of Hospital Pharmacists (EAHP), and its 36 member country platforms are creating a Common Training Framework for the hospital pharmacy education in Europe. The goal of this project is to allow the free movement of hospital pharmacists within the European Union.
The European Association of Hospital Pharmacists (EAHP) and the European Society of Clinical Pharmacy (ESCP) have collaboratively developed the Oath to Society. The Oath to Society is all encompassing and acts as a contract for excellence in providing compassionate patient care, working as part of the healthcare team and advancing the pharmacy profession, and showcasing how clinical and hospital pharmacists work every day
A day created to highlight the importance and to celebrate the work done by hospital pharmacies. This day celebrates all hospital pharmacy teams.
Catch up with EAHP’s press releases
Find all EAHP relevant publication like the EAHP Surveys, annual reports and the history books.
The European Journal of Hospital Pharmacy (EJHP) is the only official journal of the European Association of Hospital Pharmacists (EAHP) and is committed to advancing the science, practice and profession of hospital pharmacy. As the premier communication platform for hospital pharmacists worldwide, EJHP is a major source for continuing education as well as updates on advances in the practice and standard of pharmaceutical care for patients.
When EAHP and Hospital pharmacists appear in the news.
EAHP publishes a monthly EU monitor with updates about the latest EAHP initiatives and information relevant for the hospital pharmacy profession.
Sponsor Channel
The Sponsor Channel is designed to maximise visibility and engagement, allowing sponsors to connect with the hospital pharmacy community and partners in a dynamic and interactive environment. From product demonstrations to networking sessions, the Sponsor Channel offers a range of opportunities for sponsors to showcase their offerings and generate leads in the new EAHP Website.
De Rijdt, Thomas
Linked to EAHP Statements
Section 1 – Introductory Statements and Governance: Statements 1.1, 1.2, 1.3
Section 4 – Clinical Pharmacy Services: Statements 4.1, 4.2
Section 5 – Patient Safety and Quality Assurance: Statements 5.4
Section 6 – Education and Research: Statements 6.4, 6.5
ACPE UAN: 0475-0000-21-033-L05-P. A knowledge-based activity.
Abstract
In spring 2020 the world was struck that a ‘simple’ viral outbreak in China could take worldwide proportions and our society was not prepared to handle it. Little was known about this new enemy and its epidemiology. There was no vaccine and our classic pharmacological arsenal was inadequate to respond properly.
Researchers, pharmaceutical companies and financers worldwide joined forces to find a potential cure and to develop a vaccine. Over 1,500 existing molecules were tested as a potential candidate for therapy. These old drugs and compounds were tested in the lab in order to evaluate if these fit for repurposing. Some of them were tested clinically (eg. hydroxychloroquine, favipiravir, azithromycin, …) with differing outcomes. Also new therapies (eg. convalescent plasma) were tested. Next to antiviral agents, also supporting drugs such as dexamethasone, intensified anticoagulation and immunomodulators were investigated. Our understanding of the virus and the insights in treatment changed quickly and is still increasing.
New therapies in new physiopathological conditions of the patient lead to new drug interactions and the need for therapeutic drug monitoring. The hospital pharmacist has an active role in the check of appropriateness of therapy and reporting of adverse drug events as well as in writing the IMPD for clinical trials with covid19-medication. Next to pharmacotherapeutic support, also logistic hurdles such as timely provision of medication and hand alcohol, management of drug shortages, … had to be taken to manage the covid19 pandemic.
Together with measures as physical distancing, hand hygiene, the proper use of personal protection equipment and lab-testing these new therapeutic insights must help us until an effective vaccine is available.
In this session we provide an overview of the current knowledge about the disease, antiviral and supportive treatment and the development of a vaccine, as well as the way to get there. We do this from both the virologist’s and hospital pharmacist’s perspective.
Learning objectives
After the session, participants should be able to:
Education need addressed
The covid19 pandemic brings a lot of new challenges and a new reality. To respond timely and properly to the hurdles, the hospital pharmacist must understand the epidemiology and characteristics of this infection and must be able to discuss the pharmacological issues of the new treatment options and must be able to assess the efficacy and safety of current covid19 vaccines.
Keywords: Covid19, vaccine, antiviral agents, viral infections, anticoagulation, critical care, inter-professional, pharmaceutical care.
